Anaplastic large-cell lymphoma
Drug research and approvals for anaplastic large-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 24 studies of anaplastic large-cell lymphoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 24
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)NCT07750886 · Not reported · Natera, Inc. · starts Jul 27, 2026
- Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaNCT07691450 · Phase 1 · City of Hope Medical Center · starts Jan 3, 2027
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaNCT07388563 · Phase 1 · National Cancer Institute (NCI) · starts Mar 26, 2026
- Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaNCT07300514 · Phase 3 · Fudan University · starts Mar 27, 2026
- Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLNCT07013565 · Phase 2 · New York Medical College · starts Aug 7, 2025
- A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma…NCT07001384 · Phase 1 · Memorial Sloan Kettering Cancer Center · starts Aug 8, 2025
- Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With…NCT06724237 · Phase 3 · Eastern Cooperative Oncology Group · starts Jun 18, 2025
- Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise…NCT06561048 · Phase 3 · Corvus Pharmaceuticals, Inc. · starts Oct 2, 2024
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaNCT06508463 · Phase 1 · Mayo Clinic · starts Jan 5, 2024
Approved 1
- Brentuximab vedotinTubulin inhibitor
Phase 3 2
- MethotrexateDihydrofolate reductase inhibitor
- BexaroteneRetinoid X receptor agonist
Phase 2 12 of 33
- CyclophosphamideDNA inhibitor
- CytarabineDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- PrednisoneGlucocorticoid receptor agonist
- TanespimycinHeat shock protein HSP90 inhibitor
- CisplatinDNA inhibitor
- IfosfamideDNA inhibitor
- VinorelbineTubulin inhibitor
- Yttrium y 90 ibritumomab tiuxetanB-lymphocyte antigen CD20 binding agent
- VincristineTubulin inhibitor
- CrizotinibHepatocyte growth factor receptor inhibitor
Phase 1 or earlier 8
- CarboplatinDNA inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- DasatinibTyrosine-protein kinase ABL inhibitor
- ImatinibTyrosine-protein kinase ABL inhibitor
- PralatrexateDihydrofolate reductase inhibitor
- Bortezomib26S proteasome inhibitor
- CyanocobalaminSupplement
- Folic acid
How its trials ended
207 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 70 whose ending is known, 44% met their primary endpoint, 4% missed it and 51% stopped early.
- Completed, result not reported8642%
- Ongoing3818%
- Met its primary endpoint3115%
- Stopped: other or unclear2311%
- Status unknown136%
- Stopped: enrollment or feasibility52%
- Missed its primary endpoint31%
- Stopped: lack of efficacy31%
- Stopped: sponsor or business decision31%
- Stopped: funding21%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jul 19, 2013 | A phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase…Ceritinib (LDK378) | Novartis Pharmaceuticals | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA